Protheragen Obesity



ICG001

Cat. No.:	OB0225WX-1710
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR.
Size:	1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	ICG001 is a transcriptional antagonist that specifically binds to the CREB-bindi ng protein (CBP) with an IC50 of 3 μM, effectively blocking Wnt/β-catenin/TCF-me diated transcription without affecting the related coactivator p300.

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com

Protheragen
Obesity



Synonym	ICG-001; 847591-62-2; ICG 001; (*S*,*S*)-ICG 001; (6*S*,9a*S*)-*N*-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahy dro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide; (6*S*,9a*S*)-6-(4-hydr oxybenzyl)-*N*-benzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxo-hexahydro-2H-pyra zino[1,2-a]pyrimidine-1(6H)-carboxamide; (6*S*,9a*S*)-*N*-benzyl- 6-[(4-hydroxyphenyl)methyl]-8-(naphthalen-1-ylmethyl)-4,7-dioxo-3,6,9,9a-tetrahy dro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide; (5*R*,6*S*,9a*S*) -*N*-benzyl-6-[(4-hydroxyphenyl)methyl]-8-[(naphthalen-1-yl)methyl]-4,7-dio xohexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide; (6*S*,9a*S*)-6-(4-Hydroxybenzyl)-8-[(naphthalen-1-yl)methyl]-4,7-dioxohexahydropyrazino[1, 2-a]pyrimidine-1-carboxylic acid *N*-benzylamide; PRI 724; (6*S*,9a *S*)-*N*-benzyl-6-[(4-hydroxyphenyl)methyl]-8-[(naphthalen-1-yl)methyl]-4 ,7-dioxo-octahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide; (6*R*,9a*R*)-rel-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dio xo-*N*-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine- 1(6H)-carboxamide; (6*S*,9a*S*)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-diox o-*N*-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-car boxamide; (6*S*,9as)-hexahydro-6-((4-hydroxyphenyl)methyl)-8-(1-naphthaleny lmethyl)-4,7-dioxo-n-(phenylmethyl)-2h-pyrazino(1,2-a)pyrimidine-1(6h)-carboxam ide; (6*S*,9a*S*)-*N*-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrimido[1,2-a]pyrazine-1-carboxamide
CAS No.	847591-62-2
Compound CID	11238147
Formula	$C_{33}H_{32}N_4O_4$
Formula Weight	548.63

Specification

Targets&IC50	CBP: 3 μM
Relative Density	1.37 g/cm^3
IUPAC Name	(6*S*,9a*S*)-*N*-Benzyl-6-[(4-hydroxyphenyl)methyl]-8-(naphthalen -1-ylmethyl)-4,7-dioxo-3,6,9,9a-tetrahydro-2*H*-pyrazino[1,2-a]pyrimidine-1 -carboxamide
InChI	InChI=1S/C33H32N4O4/c38-27-15-13-23(14-16-27)19-29-32(40)35(21-26-11-6-10-25-9-4-5-12-28(25)26)22-30-36(18-17-31(39)37(29)30)33(41)34-20-24-7-2-1-3-8-24/h1-16,29-30,38H,17-22H2,(H,34,41)/t29-,30+/m0/s1
InChI Key	HQWTUOLCGKIECB-XZWHSSHBSA-N
SMILES string	C1CN([C@H]2CN(C(=O)[C@@H](N2C1=O)CC3=CC=C(C=C3)O)CC4=CC=CC5=CC=CC=C54)C(=O)NCC6=CC=CC=C6
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	ICG001 is employed in molecular biology to study the selective inhibition of the beta-catenin/CBP interaction and its role in regulating cellular differentiatio n versus proliferation.

Library Information

Target	Wnt/β-Catenin; Epigenetic reader domain
Receptor	CBP; Wnt/β-Catenin
Pathways	Cytoskeletal signaling; Stem cells; Chromatin/Epigenetic
Plate Number	AOCL-22
Plate Location	h5
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	40 mg/mL; 72.91 mM
Ethanol Max Solubility	27.4 mg/mL; 50 mM

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com